Showing 701-710 of 2222 results for "".
- Fenfluramine May Usher in Higher Standards for Treatment of Dravet Syndromehttps://practicalneurology.com/news/fenfluramine-may-usher-in-higher-standards-for-treatment-of-dravet-syndrome/2469642/In an editorial in Epilepsy and Behavior, Helen Cross, MD and Joseph Sullivan, MD suggest fenfluramine (Fintepla; Zogenix, Emeryville, CA) clinical trial results can raise the bar for efficacy of antiseizure medications (ASMs) for
- Significant Variance in Outcomes Found in Danish MS Hospitals Rehabilitation Studyhttps://practicalneurology.com/news/significant-variance-in-outcomes-found-in-danish-ms-hospitals-rehabilitation-study/2470205/Results from the Danish MS Hospitals Rehabilitation Study presented at the 2023 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) found that multidisciplinary rehabilitation (M
- Safety Profiles Similar for Standard and Extended-Interval Dosing of Natalizumab in for Multiple Sclerosishttps://practicalneurology.com/news/safety-profiles-similar-for-standard-and-extended-interval-dosing-of-natalizumab-in-for-multiple-sclerosis/2469899/A study (NCT03689972) was done to assess potential differences in safety and efficacy with different dosing schedules of natalizumab (BG00002; Biogen, Cambridge, MA) for relapsing-remitting m
- Award Recipients Recognized at the 2024 International Congress of Parkinson’s Disease and Movement Disordershttps://practicalneurology.com/news/award-recipients-recognized-at-the-2024-international-congress-of-parkinsons-disease-and-movement-disorders/2470598/The International Parkinson’s Disease and Movement Disorders Society (MDS) has announced recipients of the 2024 MDS Awards. The awards honor professionals in the field who are elevating care for movement disorders through their contributions to research, scholarship, and clinical work. The
- FDA Approves Mirabegron for Neurogenic Detrusor Overactivity in Pediatric Patientshttps://practicalneurology.com/news/fda-approves-mirabegron-for-neurogenic-detrusor-overactivity-in-pediatric-patients/2469543/The Food and Drug Administration approved a new indication for mirabegron extended-release tablets (Myrbetriq; Silver Spring, MD) and mirabegron for extended-release oral suspension (Myrbetriq Granules; Silver Spring, MD) to treat neurogenic detrusor overactivity (NDO) in children age 3 yea
- Orphan Drug Designation Granted by FDA for First Exon 44 Skipping Drug for Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/orphan-drug-designation-granted-by-fda-for-first-exon-44-skipping-drug-for-duchenne-muscular-dystrophy/2470263/Investigational antisense oligonucleotide brogidirsen (NS-089/NCNP-02; NS Pharma, Paramus, NJ) has been granted orphan drug designation by the Food and Drug Administration (FDA) for the treatment of patients with Duchenne m
- Study Suggests Inadequate Provider-Patient Communication Surrounding Medication-Overuse Headache in Migraine Patientshttps://practicalneurology.com/news/study-suggests-inadequate-provider-patient-communication-surrounding-medication-overuse-headache-in-migraine-patients/2470214/The results of a study presented at the 2023 Annual Scientific Meeting of the American Headache Society (AHS) reported an overall lack of patient awareness and provider communication regarding medication-overuse headache (M
- International Advisory Committee on Clinical Trials in Multiple Sclerosis Suggests New Framework for Defining Progression of Multiple Sclerosishttps://practicalneurology.com/news/international-advisory-committee-on-clinical-trials-in-multiple-sclerosis-suggests-new-framework-for-defining-progression-of-multiple-sclerosis/2470199/The International Advisory Committee on Clinical Trials in Multiple Sclerosis proposed a new mechanism-driven framework for defining progression in multiple sclerosis (MS). The recommendations presented at the 2023 Annual M
- Rozanolixizumab Improves in Activities of Daily Living in Individuals with Generalized Myasthenia Gravishttps://practicalneurology.com/news/rozanolixizumab-improves-in-activities-of-daily-living-in-individuals-with-generalized-myasthenia-gravis/2469777/In the phase 3 MycarinG study1 (NCT03971422), adults with generalized myasthenia gravis (gMG) treated with 1 of 2 doses of rozanolixizumab (UCB7665; Creative Biolabs, Shirley, NY) vs placebo had m
- First Participant Enrolled in Phase 3 Study of Vidofludimus Calcium for Relapsing Multiple Sclerosishttps://practicalneurology.com/news/first-participant-enrolled-in-phase-3-study-of-vidofludimus-calcium-for-relapsing-multiple-sclerosis/2469761/The first participant has enrolled in the phase 3 ENSURE-1 clinical trial (NCT05134441) of vidofludimus calcium (IMU-838; Immunic Therapeutics, New York, NY) for potential treatment of relapsing m